Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03346642 Recruiting - Clinical trials for Primary Mediastinal Large B-cell Lymphoma

Combination of GVD and SHR-1210 With or Without Decitabine Priming in Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Start date: June 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) will receive GVD chemotherapy and PD-1 antibody(SHR-1210) with or without low-dose Decitabine priming. The safety and feasibility of combined regimens will be evaluated in phase I study. The subsequent phase II study will access the efficacy of the combined regimens.

NCT ID: NCT03346096 Not yet recruiting - Malignant Lymphoma Clinical Trials

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

TEAM
Start date: December 2017
Phase: Phase 2
Study type: Interventional

Study is designed to explore whether the introduction of Thiotepa, to the pre autologous stem-cell transplantation (ASCT) conditioning will reduce toxicity and thus improve outcome following transplantation in up to 24 patients with malignant lymphoma including both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma ( HL) improving toxicity profile , reducing side effects while potentially improving the antitumor response. Specifically,we speculate that using the novel Thiotepa based TEAM consisted of THIOTEPA 5mg/kg on days -7-6, etoposide 200 mg/m2 , Cytosar (ARA-C) 200 mg/m2 on days -5,-4, -3, -2 and melphalan 140 mg/m2 on day -1, pre transplantation conditioning regimen may allow transplantation with lower transplant related toxicity and thus improve outcome in this setting. Toward this aim the impact on toxicity profile ,engraftment and disease control will be assessed.

NCT ID: NCT03344809 Recruiting - Lymphoma Clinical Trials

Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing

ENABLE-NGS
Start date: August 2016
Phase: N/A
Study type: Observational

To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.

NCT ID: NCT03344367 Recruiting - Clinical trials for Non Hodgkin Lymphoma

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Start date: November 2017
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.

NCT ID: NCT03343665 Recruiting - Hodgkin Lymphoma Clinical Trials

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Nivo40
Start date: August 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II trial to evaluate the safety and efficacy of nivolumab at the fixed dose 40 mg in patients with relapsed or refractory Hodgkins lymphoma.

NCT ID: NCT03343652 Recruiting - Hodgkin's Lymphoma Clinical Trials

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NB001
Start date: May 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.

NCT ID: NCT03342586 Recruiting - Clinical trials for Central Nervous System Lymphoma

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Start date: November 7, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monitoring central nervous system lymphoma.

NCT ID: NCT03341520 Not yet recruiting - Clinical trials for Stage II Follicular Lymphoma Grade 2

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

GAZAI
Start date: November 2017
Phase: Phase 2
Study type: Interventional

Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders. Primary Objective: Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in combination with Gazyvaro (Obinutuzumab) in early stage nodal follicular lymphoma in order to avoid conventional full dose IF radiotherapy. Secondary Objective: Efficacy and safety of a response adapted radiation dose treatment schedule.

NCT ID: NCT03340766 Not yet recruiting - Clinical trials for Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

Start date: January 31, 2018
Phase: Phase 1
Study type: Interventional

Phase 1b: To determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adult subjects with relapsed or refractory (r/r) DLBCL

NCT ID: NCT03338881 Not yet recruiting - Clinical trials for Advanced Solid Neoplasms

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Start date: November 17, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659 solution containing 60 to 80 micro curie (Ci) of total radioactivity in participants with advanced solid tumors and/or lymphomas.